SAN DIEGO--(BUSINESS WIRE)--Cytonus Therapeutics Inc., a biotechnology company developing new platforms for delivering biologics, announced today that it will be presenting preclinical data for its Cargocyte™ technology platform program targeting difficult to treat Breast Cancer at the BIO International Convention meeting June 3-6 in Philadelphia, PA.
Cargocytes are engineered allogenic cell lines that can carry a variety of payloads like small molecule compounds, gene editing therapies, therapeutic RNAs, and powerful biologics such as immune modulating cytokines, antibodies and oncolytic viruses.
“We are honored to have been selected to present Cytonus’ first-of-its-kind Cargocyte™ technology platform at this year’s BIO convention and look forward to sharing our promising CA-IL12 data in treating Triple Negative Breast Cancer in preclinical animal models,” said Remo Moomiaie-Qajar, M.D., president and CEO of Cytonus.
Details of the presentation:
|Company Name:||Cytonus Therapeutics, Inc.|
|Presentation Date:||Thursday, June 6|
|Presentation Time:||1:30:00 PM|
|Presentation Room:||Theater 1|
|Speaker:||Remo Moomiaie-Qajar, M.D., CEO|
Statements in this news release, which relate to other than strictly historical facts, such as statements about Cytonus’ plans and strategies, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for its products are forward-looking statements. The words "believe," "expect," "anticipate," "estimate," "project," and similar expressions identify forward-looking statements that speak only as of the date hereof. Such statements involve risks and uncertainties that could cause actual results to differ materially from anticipated results due to many factors, including regulatory and development risks. Cytonus undertakes no obligation to publicly update or revise any forward-looking statements. This news release is neither an offer to sell, nor the solicitation of any offer to purchase, any security.